Tenofovir Disoproxil Fumarate in Late Pregnancy to Prevent Vertical Transmission of Hepatitis B Virus in Highly Viremic Mothers

Trial Profile

Tenofovir Disoproxil Fumarate in Late Pregnancy to Prevent Vertical Transmission of Hepatitis B Virus in Highly Viremic Mothers

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 19 Jun 2017

At a glance

  • Drugs Tenofovir (Primary)
  • Indications Hepatitis B
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors New Discovery
  • Most Recent Events

    • 14 Jun 2017 Planned End Date changed from 1 Sep 2013 to 28 Oct 2017.
    • 16 Jun 2016 Primary endpoint of number of infants who have HBV infection at the age of 28 weeks (mother-to-child transmission) has been met, according to results published in the New England Journal of Medicine.
    • 16 Jun 2016 Results published in the New England Journal of Medicine
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top